Search
HCW Biologics Inc
HCWBAdd to Watchlist
4.300USD
-0.280-6.11%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.10MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-6.11%
5 Days
+317.48%
1 Month
+163.80%
6 Months
+283.93%
Year to Date
+343.02%
1 Year
+5.91%
Key Figures
4.490Open
4.740High
102.07KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.11%Turnover Ratio
4.580Prev. Close
4.220Low
350.83KTurnover
LossP/E Static
5.10P/B
0.00%Div Yield TTM
-8.54%ROA
8.74652wk High
0.99Volume Ratio
-30.02MNet Profit
3.28MShares
-8.2976EPS TTM
2.07Beta
-27725.80%ROE
0.25052wk Low
11.35%Amplitude
99.83%Gross Margin
14.10MMarket Cap
15.83Reward/Risk
11.43%Risk Rate
TradingKey Stock Score of HCW Biologics Inc
Currency: USD Updated: 2026-07-02Key Insights
HCW Biologics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 121 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HCW Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
HCW Biologics Inc Highlights
StrengthsRisks
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 54.23K.
Fairly Valued
The company’s latest PE is -0.52, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 465.64K shares, increasing 39.47% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.84.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
30.000
Target Price
+555.02%
Upside Space
HCW Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
HCW Biologics Inc Info
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Ticker SymbolHCWB
CompanyHCW Biologics Inc
CEOWong (Hing C)
Websitehttps://hcwbiologics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of HCW Biologics Inc (HCWB)?
The current price of HCW Biologics Inc (HCWB) is 4.30.
What is the symbol of HCW Biologics Inc?
The ticker symbol of HCW Biologics Inc is HCWB.
What is the 52-week high of HCW Biologics Inc?
The 52-week high of HCW Biologics Inc is 8.75.
What is the 52-week low of HCW Biologics Inc?
The 52-week low of HCW Biologics Inc is 0.25.
What is the market capitalization of HCW Biologics Inc?
The market capitalization of HCW Biologics Inc is 14.10M.
Is HCW Biologics Inc (HCWB) currently rated as Buy, Hold, or Sell?
According to analysts, HCW Biologics Inc (HCWB) has an overall rating of Buy, with a price target of 30.00.
What is the Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB)?
The Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB) is -10.63.